Literature DB >> 27529763

Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.

Kai Duan1,2, Ozgur Mete1,2,3.   

Abstract

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms with distinct biological behaviors, depending on the site of origin and the degree of tumor proliferation. Although advances in biochemical and radiological modalities have enhanced the ability to detect NETs, tissue diagnosis remains the gold standard to assess tumor characteristics for treatment decision making. In an era with growing demands for precision diagnostics based on smaller tissue samples, immunohistochemistry has become an indispensable tool in the pathologist's repertoire. In conjunction with clinical findings and cytomorphology, complementary use of 1) markers of neuroendocrine differentiation, 2) markers confirming epithelial nature, 3) markers of cellular proliferation, 4) transcription factors and hormonal markers, as well as 5) predictive and prognostic markers may be necessary to guide patient management in NETs. The current review summarizes common applications of these immunohistochemical markers when confronted with a potential neuroendocrine neoplasm, and proposes a stepwise algorithmic approach to avoid diagnostic errors in targeted biopsies. Cancer Cytopathol 2016;124:871-884.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  biomarkers; hormones; immunohistochemistry; neuroendocrine tumor; paraganglioma; poorly differentiated neuroendocrine carcinoma; transcription factors

Mesh:

Substances:

Year:  2016        PMID: 27529763     DOI: 10.1002/cncy.21765

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  25 in total

1.  MEN2 Syndrome-Related Medullary Thyroid Carcinoma with Focal Tyrosine Hydroxylase Expression: Does It Represent a Hybrid Cellular Phenotype or Functional State of Tumor Cells?

Authors:  Ozgur Mete; Ahmed Essa; Anil Bramdev; Navendren Govender; Runjan Chetty
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

Review 2.  Fit-for-Purpose Immunohistochemical Biomarkers.

Authors:  Emina Emilia Torlakovic
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 3.  Neuroendocrine Tumors of the Thyroid and Their Mimics.

Authors:  Virginia A Livolsi
Journal:  Endocr Pathol       Date:  2021-03-09       Impact factor: 3.943

Review 4.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

5.  Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas.

Authors:  Hasan Gucer; Sultan Caliskan; Mehmet Kefeli; Ozgur Mete
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

Review 6.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 7.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 8.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

9.  Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients.

Authors:  Yigong Zhang; Cong Li; Ming Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

10.  Survival outcomes and prognostic factors of primary small cell carcinoma of the esophagus.

Authors:  Huikai Miao; Rongzhen Li; Dongni Chen; Jia Hu; Youfang Chen; Zhesheng Wen
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.